Innate Pharma SA Operating Expense
Innate Pharma SA (IPHYF) reported Operating Expense of EUR 63.01 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:OperatingExpense · last filed 2026-04-01
| Period end | Operating Expense 6 month | Operating Expense 6 month as first filed | Operating Expense 12 month | Operating Expense 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | 63.01M EUR 20-F · filed 2026-04-01 | |||
| 2025-06-30 | 30.29M EUR 6-K · filed 2025-09-17 | |||
| 2024-12-31 | 71.70M EUR 20-F · filed 2026-04-01 | |||
| 2024-06-30 | 38.66M EUR 6-K · filed 2025-09-17 | |||
| 2023-12-31 | 74.31M EUR 20-F · filed 2026-04-01 | |||
| 2023-06-30 | 40.60M EUR 6-K · filed 2024-09-12 | |||
| 2022-12-31 | 115.10M EUR 20-F · filed 2025-04-30 | |||
| 2022-06-30 | 37.10M EUR 6-K · filed 2023-09-14 | |||
| 2021-12-31 | 72.53M EUR 20-F · filed 2024-04-04 | |||
| 2021-06-30 | 33.85M EUR 6-K · filed 2022-09-15 | 41.12M EUR 6-K · filed 2021-09-15 | ||
| 2020-12-31 | 68.69M EUR 20-F · filed 2023-04-06 | 133.39M EUR 20-F · filed 2021-04-27 | ||
| 2020-06-30 | 45.99M EUR 6-K · filed 2021-09-15 | |||
| 2019-12-31 | 83.87M EUR 20-F · filed 2022-04-04 | 104.65M EUR 20-F · filed 2020-04-24 | ||
| 2018-12-31 | 87.70M EUR 20-F · filed 2021-04-27 | |||
| 2017-12-31 | 84.02M EUR 20-F · filed 2020-04-24 |